<font color="#000000"><font size="4"><font face="verdana,sans-serif">This a very critical point, John. The challenge will be to perform xenodiagnosis in a population of dogs! Besides, resides the question of many sand flies would be necessary to guarantee that the dogs are not infective. Also, when the xeno should be performed, when to dissect, what technique to use for detecting infection and what is the type of challenge the will mimick natural infections.</font></font></font><div>
<font color="#000000"><font size="4"><font face="verdana,sans-serif">So, you are right (for either human and collective point of views), but there are still many other steps to be acomplished. Cheers, Carlos.<br></font></font></font><br>
<div class="gmail_quote">2011/9/26 John David <span dir="ltr"><<a href="mailto:jdavid@hsph.harvard.edu">jdavid@hsph.harvard.edu</a>></span><br><blockquote class="gmail_quote" style="margin:0 0 0 .8ex;border-left:1px #ccc solid;padding-left:1ex;">
<div style="word-wrap:break-word"><p class="MsoNormal"></p><p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;text-autospace:none"><span style="font-family:Helvetica">I think that for any vaccine developed to protect dogs
against VL, but which is also meant to prevent transmission of VL to humans, the developers should
show that after the vaccinated dog has been challenged with Leishmania, it does not transmit Leishmania to sand flies.<u></u><u></u></span></p><p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;text-autospace:none">
John R David, M.D.</p><p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;text-autospace:none"><span style="font-family:Helvetica">Richard Pearson Strong Professor
Emeritus</span><span style="font-size:14.0pt;font-family:Helvetica"><u></u><u></u></span></p><p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;text-autospace:none"><span style="font-family:Helvetica">Department of
Immunology and Infectious Diseases</span><span style="font-size:14.0pt;font-family:Helvetica"><u></u><u></u></span></p><p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;text-autospace:none"><span style="font-family:Helvetica">Harvard School of Public Health</span><span style="font-size:14.0pt;font-family:Helvetica"><u></u><u></u></span></p>
<p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;text-autospace:none"><span style="font-family:Helvetica">Professor of
Medicine, Harvard Medical School</span><span style="font-size:14.0pt;font-family:Helvetica"><u></u><u></u></span></p><p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;text-autospace:none"><span style="font-family:Helvetica">300 W. 23rd Street, Apt. 13K</span><span style="font-size:14.0pt;font-family:Helvetica"><u></u><u></u></span></p>
<p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;text-autospace:none"><span style="font-family:Helvetica">New York, NY, 10011</span><span style="font-size:14.0pt;font-family:Helvetica"><u></u><u></u></span></p>
<p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;text-autospace:none"><span style="font-family:Helvetica">Tel: <a href="tel:212%20414%208646" value="+12124148646" target="_blank">212 414 8646</a></span><span style="font-size:14.0pt;font-family:Helvetica"><u></u><u></u></span></p>
<p class="MsoNormal" style="margin-bottom:0in;margin-bottom:.0001pt;text-autospace:none"><span style="font-family:Helvetica">Email: <a href="mailto:jdavid@hsph.harvard.edu" target="_blank">jdavid@hsph.harvard.edu</a></span><span style="font-size:14.0pt;font-family:Helvetica"><u></u><u></u></span></p>
<p class="MsoNormal"><span style="font-family:Helvetica"><u></u> <u></u></span></p>
<p></p><div><div></div><div class="h5"><p class="MsoNormal">
</p>
<div><div><br></div><div>On Sep 19, 2011, at 12:04 AM, Dr GR Rajasekariah wrote:</div><br><blockquote type="cite"><div>Hello EveryOne,<br>I am responding to the topic on European VL Dog vaccine.<br>It is a great challenge in devising a protective vaccine against visceral leishmaniasis in dogs. This point equally applies the same challenge for human situation.<br>
Because Th-2 response is so dominant during VL infection, modulating Th-2 into Th-1 response is a big challenge to immunologists.<br><br>Key points lies in the presentation of appropriate antigen in appropriate dose to stimulate the Th-1 dependent protective immune response.<br>
I understand several vaccines are in the market and real efficacy of these vaccines will come out once introduced to field conditions.<br><br>I just wanted to inform you that we have a suitable antibody kit for testing the immunopotentiation in dogs following vaccination of dogs.<br>
Our assay is based on the released promastigote antigens.<br>It is a highly sensitive assay.<br>Currently we supply reagents for determination of total IgG antibodies in serum.<br>If any particular group is interested then we are able to provide appropriate reagent for detection of specific IgG2 and other isotype specific antibody detection.<br>
Because our antibody detection ELISA is based on the exo-antigens such an ELISA would be of exceptional type for measuring antibody response in vaccinated animals.<br>Highly suitable for diagnosing dogs responded to vaccines.<br>
<br>Recently I came to know that some of commercial kits were found to be not useful for detecting seroconversion in dogs vaccinated with FML vaccine (Leish-Immune) in Brazil.<br>Because we use released antigens in our kit, any such problems will overcome if they use Canine Leish IgG CELISA (Manufacturer Cellabs Pty Ltd Brookvale NSW Australia email <a href="mailto:sales@cellabs.com.au" target="_blank">sales@cellabs.com.au</a>).<br>
If any one is interested to know more about our antibody detection ELISA based on exo-antigens please contact us.<br><br>This is for your kind information.<br><br>Dr GR Rajasekariah<br>Sydney<br>Australia<br><a href="mailto:raj@cellabs.com.au" target="_blank">raj@cellabs.com.au</a><br>
<br><br><br><br><br><br>----- Original Message ----- From: <<a href="mailto:leish-l-request@lineu.icb.usp.br" target="_blank">leish-l-request@lineu.icb.usp.br</a>><br>To: <<a href="mailto:leish-l@lineu.icb.usp.br" target="_blank">leish-l@lineu.icb.usp.br</a>><br>
Sent: Wednesday, August 10, 2011 5:18 PM<br>Subject: Leish-l Digest, Vol 44, Issue 3<br><br><br><blockquote type="cite">Send Leish-l mailing list submissions to<br></blockquote><blockquote type="cite"><a href="mailto:leish-l@lineu.icb.usp.br" target="_blank">leish-l@lineu.icb.usp.br</a><br>
</blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">To subscribe or unsubscribe via the World Wide Web, visit<br></blockquote><blockquote type="cite"><a href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l" target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a><br>
</blockquote><blockquote type="cite">or, via email, send a message with subject or body 'help' to<br></blockquote><blockquote type="cite"><a href="mailto:leish-l-request@lineu.icb.usp.br" target="_blank">leish-l-request@lineu.icb.usp.br</a><br>
</blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">You can reach the person managing the list at<br></blockquote><blockquote type="cite"><a href="mailto:leish-l-owner@lineu.icb.usp.br" target="_blank">leish-l-owner@lineu.icb.usp.br</a><br>
</blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">When replying, please edit your Subject line so it is more specific<br></blockquote><blockquote type="cite">than "Re: Contents of Leish-l digest..."<br>
</blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">Today's Topics:<br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">
1. European VL Dog Vaccine - CaniLeish?: (jeffrey shaw)<br>
</blockquote><blockquote type="cite"> 2. Re: FW: Leishmaniasis Pathology Network (Moazzem Hossain)<br></blockquote><blockquote type="cite"> 3. Re: FW: Leishmaniasis Pathology Network (Moazzem Hossain)<br></blockquote><blockquote type="cite">
<br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">----------------------------------------------------------------------<br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">
Message: 1<br></blockquote><blockquote type="cite">Date: Tue, 9 Aug 2011 15:18:44 +0000<br></blockquote><blockquote type="cite">From: jeffrey shaw <<a href="mailto:jayusp@hotmail.com" target="_blank">jayusp@hotmail.com</a>><br>
</blockquote><blockquote type="cite">Subject: [Leish-l] European VL Dog Vaccine - CaniLeish?:<br></blockquote><blockquote type="cite">To: Leish-L <<a href="mailto:leish-l@lineu.icb.usp.br" target="_blank">leish-l@lineu.icb.usp.br</a>><br>
</blockquote><blockquote type="cite">Message-ID: <COL101-W1CDD4171D44B715B795E9CB200@phx.gbl><br></blockquote><blockquote type="cite">Content-Type: text/plain; charset="windows-1252"<br></blockquote><blockquote type="cite">
<br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">CaniLeish?:<br></blockquote><blockquote type="cite"> The European Commission granted a marketing authorisation valid throughout the European Union, for CaniLeish to Virbac S.A. on 14/03/2011.<br>
</blockquote><blockquote type="cite"> This vaccine, CaniLeish?, will initially be launched in Portugal at the end of the first half of 2011. This will be followed rapidly by launches in other countries in the endemic area: Spain, France, Greece and Italy (not in chronological order). This roll-out takes account of the geographical prevalence of the disease and the time required to build vaccine production up to full capacity. The launch in Northern European countries from where there is a flow of summer visitors to the endemic area will be part of a second phase.<br>
</blockquote><blockquote type="cite"> The basis of this vaccine are excreted proteins plus a saponin adjuvant purified from Quil-A. Its efficacy was determined in a 2 year open field trial.<br></blockquote><blockquote type="cite">
The vaccine is given to dogs as three injections, three weeks apart, under the skin. The first injection can be given from six months of age, the second injection is given three weeks later and the third three weeks from the second one. Afterward a single ?booster? should be given every year to maintain protection.<br>
</blockquote><blockquote type="cite">-------------- next part --------------<br></blockquote><blockquote type="cite">An HTML attachment was scrubbed...<br></blockquote><blockquote type="cite">URL: <<a href="http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404f5e/attachment-0001.htm" target="_blank">http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404f5e/attachment-0001.htm</a>><br>
</blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">------------------------------<br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">Message: 2<br></blockquote><blockquote type="cite">
Date: Wed, 10 Aug 2011 13:07:17 +0600<br></blockquote><blockquote type="cite">From: Moazzem Hossain <<a href="mailto:directordcbd@gmail.com" target="_blank">directordcbd@gmail.com</a>><br></blockquote><blockquote type="cite">
Subject: Re: [Leish-l] FW: Leishmaniasis Pathology Network<br></blockquote><blockquote type="cite">To: jeffrey shaw <<a href="mailto:jayusp@hotmail.com" target="_blank">jayusp@hotmail.com</a>>, "Prof. Paul Kaye"<br>
</blockquote><blockquote type="cite"><<a href="mailto:paul.kaye@york.ac.uk" target="_blank">paul.kaye@york.ac.uk</a>><br></blockquote><blockquote type="cite">Cc: "Prof. Dr. Moazzem Hossain" <<a href="mailto:profdrmoazzemhossain@gmail.com" target="_blank">profdrmoazzemhossain@gmail.com</a>>,<br>
</blockquote><blockquote type="cite">Leish-L <<a href="mailto:leish-l@lineu.icb.usp.br" target="_blank">leish-l@lineu.icb.usp.br</a>><br></blockquote><blockquote type="cite">Message-ID:<br></blockquote><blockquote type="cite">
<CAE-TCmS=i=WaT8cAeOXUJmot=<a href="mailto:KPvMQSLKar6CTfuUBK9M9tsUw@mail.gmail.com" target="_blank">KPvMQSLKar6CTfuUBK9M9tsUw@mail.gmail.com</a>><br></blockquote><blockquote type="cite">Content-Type: text/plain; charset=windows-1252<br>
</blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">10 Aug 2011<br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">Dear Professor Paul Kaye,<br></blockquote><blockquote type="cite">
<br></blockquote><blockquote type="cite">Thank you for your email. Please find attached our supportive letter<br></blockquote><blockquote type="cite">of interest for Leishmaniasis Pathology Network.<br></blockquote><blockquote type="cite">
Looking forward for your kind response.<br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">Best regards.<br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite"><br>
</blockquote>
<blockquote type="cite">-- <br></blockquote><blockquote type="cite">*Prof. Dr. Moazzem Hossain *<br></blockquote><blockquote type="cite">Ex - Director Disease Control<br></blockquote><blockquote type="cite">Ministry of Health & Family Welfare<br>
</blockquote><blockquote type="cite">Government of Bangladesh<br></blockquote><blockquote type="cite">*Mailing address*:<br></blockquote><blockquote type="cite">Founder Chairman and Project Director<br></blockquote><blockquote type="cite">
Institute of Allergy & Clinical Immunology of Bangladesh (IACIB)<br></blockquote><blockquote type="cite">Room 4 - 5 (2nd Floor), Green Super Market, Green Road<br></blockquote><blockquote type="cite">Dhaka -1205, Bangladesh.<br>
</blockquote><blockquote type="cite">Phone:880-2-8115646 (O )<br></blockquote><blockquote type="cite"> 880-1715038551(Mobile)<br></blockquote><blockquote type="cite">Email: <a href="mailto:directordcbd@gmail.com" target="_blank">directordcbd@gmail.com</a><br>
</blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">
<br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">On 8/9/11, jeffrey shaw <<a href="mailto:jayusp@hotmail.com" target="_blank">jayusp@hotmail.com</a>> wrote:<br>
</blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Date: Tue, 9 Aug 2011 11:58:52 +0100<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">From: <a href="mailto:paul.kaye@york.ac.uk" target="_blank">paul.kaye@york.ac.uk</a><br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Subject: Leishmaniasis Pathology Network<br></blockquote></blockquote>
<blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote>
</blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">
<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> Dear all,<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> Invitation to participate in a global pathology<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> network for<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> research and training in leishmaniasis (LeishPathNet)<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> You may recall the Dormy House meeting in 2008<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> and some of<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> the plans we put forward? Over<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> the past<br></blockquote>
</blockquote>
<blockquote type="cite"><blockquote type="cite"> couple years, I have also spoken more to a few of you about one<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> idea that was<br></blockquote>
</blockquote><blockquote type="cite"><blockquote type="cite"> formulated at Dormy, namely of setting up a digital pathology<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> network. I have<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> also had numerous discussions with the major equipment<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> manufacturers to see if<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> any of them would be supportive of helping us to develop such an<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">
initiative. There have<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> been two major<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> develoments recently. First,<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> Carl Zeiss<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> is willing to work with us to set up an integrated global digital<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> pathology<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> network (providing a significant financial and technical<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> contribution) and<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> second, the Wellcome Trust is willing to review a pre-proposal to<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> fund the<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> initiative through their new Biomedical Resources Grant scheme<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite">(<a href="http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/Strategic-awards-and-initiatives/wtdv031727.htm" target="_blank">http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/Strategic-awards-and-initiatives/wtdv031727.htm</a>)<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> .<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> I have attached an outline of the project that<br></blockquote>
</blockquote><blockquote type="cite"><blockquote type="cite"> I had sent to<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> the Trust for their initial views, which I think is reasonably<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> self-explanatory.<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> They appeared very<br></blockquote></blockquote>
<blockquote type="cite"><blockquote type="cite"> enthusiastic! The main<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> question now is whether enough of<br></blockquote></blockquote>
<blockquote type="cite"><blockquote type="cite"> you are still supportive? [ I will also be sending this email to<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> others, but please feel free to circulate ]<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">
I think the<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> project will be<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> challenging, but success could have a real impact on the way we<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> conduct<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> business. It should serve not only as a vehicle to enhance<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> research in<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> leishmaniasis, but the model would be equally applicable across<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> a broad range<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> of diseases and global challenges (with leishmaniasis setting<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> the pace).<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> If we wish to<br></blockquote></blockquote><blockquote type="cite">
<blockquote type="cite"> proceed, the requirements<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> are that we submit a pre-proposal to the Trust by Oct 18th 2011.<br></blockquote>
</blockquote><blockquote type="cite"><blockquote type="cite"> This pre-proposal is short (4 sections of 350 words) and<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> requires<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> letters of support from the community.<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> If you are<br></blockquote>
</blockquote><blockquote type="cite"><blockquote type="cite"> supportive of the idea that<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> we try to take this forward (and there is plenty of scope for<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> later iteration<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> of the detail), I would be grateful if you could please provide<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> me with a<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> letter of support by September<br></blockquote>
</blockquote><blockquote type="cite"><blockquote type="cite"> 12th<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> 2011, indicating whether you would like to be a network<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> partner if the bid<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> is successful. You could<br></blockquote>
</blockquote><blockquote type="cite"><blockquote type="cite"> also be<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> supportive but not wish to become directly involved at this<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> stage, and such<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> letters are equally valuable. Your letter might also stress the<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> added value<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> that the network could provide, its importance for research and<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> training and/or<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> for progressing the translational agenda.<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> It would also be an opportunity to indicate whether your<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> group (or<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> institute, if multiple groups) would be interested in bidding to<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">
be one of the<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> initial ?designated laboratories?.<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> If there is<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> sufficient support to<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> proceed and if subsequently the pre-proposal is successful (we<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> will know on 22nd<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> Nov), then I will need a few volunteers to help finalise the<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> full proposal,<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> which will be due on Jan 26th 2012.<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> A funding decision will be made on May 26th<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> 2012.<br>
</blockquote>
</blockquote><blockquote type="cite"><blockquote type="cite"> Best wishes<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> and of course I am happy to<br></blockquote></blockquote><blockquote type="cite">
<blockquote type="cite"> discuss any points further (though I will be out of the UK from<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> Aug 10 ?Sept<br></blockquote></blockquote>
<blockquote type="cite"><blockquote type="cite"> 12)<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> Paul<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">
<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">
<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">
<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> --<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Professor Paul Kaye, Ph.D., FRCPath.<br></blockquote></blockquote>
<blockquote type="cite"><blockquote type="cite">Deputy Dean (Research), Hull York Medical School, and<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Director, Centre for Immunology and Infection<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Department of Biology and Hull York Medical School<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">University of York<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Wentworth Way<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">York YO10 5YW<br></blockquote></blockquote><blockquote type="cite">
<blockquote type="cite">United Kingdom<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Tel: <a href="tel:%2B44%20%280%291904%20328840" value="+441904328840" target="_blank">+44 (0)1904 328840</a><br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Fax: <a href="tel:%2B44%20%280%291904%20328844" value="+441904328844" target="_blank">+44 (0)1904 328844</a><br></blockquote></blockquote><blockquote type="cite">
<blockquote type="cite">Email: <a href="mailto:paul.kaye@york.ac.uk" target="_blank">paul.kaye@york.ac.uk</a> <mailto:<a href="mailto:paul.kaye@york.ac.uk" target="_blank">paul.kaye@york.ac.uk</a>><br></blockquote>
</blockquote>
<blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Centre Administrator and PA: Elizabeth Greensted<br></blockquote></blockquote><blockquote type="cite">
<blockquote type="cite">Tel: 01904 328845<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Email: <a href="mailto:liz.greensted@york.ac.uk" target="_blank">liz.greensted@york.ac.uk</a> <mailto:<a href="mailto:liz.greensted@york.ac.uk" target="_blank">liz.greensted@york.ac.uk</a>><br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Centre Email: <a href="mailto:cii@york.ac.uk" target="_blank">cii@york.ac.uk</a> <mailto:<a href="mailto:cii@york.ac.uk" target="_blank">cii@york.ac.uk</a>><br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Centre website: <a href="http://www.york.ac.uk/cii" target="_blank">http://www.york.ac.uk/cii</a><br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Times Higher Education University of the Year 2010<br></blockquote></blockquote>
<blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Email disclaimer: <a href="http://www.york.ac.uk/docs/disclaimer/email.htm" target="_blank">http://www.york.ac.uk/docs/disclaimer/email.htm</a><br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><br></blockquote>
<blockquote type="cite"><br></blockquote><blockquote type="cite">------------------------------<br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">Message: 3<br></blockquote><blockquote type="cite">
Date: Wed, 10 Aug 2011 13:06:47 +0600<br></blockquote><blockquote type="cite">From: Moazzem Hossain <<a href="mailto:directordcbd@gmail.com" target="_blank">directordcbd@gmail.com</a>><br></blockquote><blockquote type="cite">
Subject: Re: [Leish-l] FW: Leishmaniasis Pathology Network<br></blockquote><blockquote type="cite">To: jeffrey shaw <<a href="mailto:jayusp@hotmail.com" target="_blank">jayusp@hotmail.com</a>>, "Prof. Paul Kaye"<br>
</blockquote><blockquote type="cite"><<a href="mailto:paul.kaye@york.ac.uk" target="_blank">paul.kaye@york.ac.uk</a>><br></blockquote><blockquote type="cite">Cc: "Prof. Dr. Moazzem Hossain" <<a href="mailto:profdrmoazzemhossain@gmail.com" target="_blank">profdrmoazzemhossain@gmail.com</a>>,<br>
</blockquote><blockquote type="cite">Leish-L <<a href="mailto:leish-l@lineu.icb.usp.br" target="_blank">leish-l@lineu.icb.usp.br</a>><br></blockquote><blockquote type="cite">Message-ID:<br></blockquote><blockquote type="cite">
<CAE-TCmQNUkZdNE5w+Z20bjLC-=<a href="mailto:vvV9BCP6OLOm9f6RV-BfpXvA@mail.gmail.com" target="_blank">vvV9BCP6OLOm9f6RV-BfpXvA@mail.gmail.com</a>><br></blockquote><blockquote type="cite">Content-Type: text/plain; charset="windows-1252"<br>
</blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">10 Aug 2011<br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">Dear Professor Paul Kaye,<br></blockquote><blockquote type="cite">
<br></blockquote><blockquote type="cite">Thank you for your email. Please find attached our supportive letter<br></blockquote><blockquote type="cite">of interest for Leishmaniasis Pathology Network.<br></blockquote><blockquote type="cite">
Looking forward for your kind response.<br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">Best regards.<br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite"><br>
</blockquote>
<blockquote type="cite">-- <br></blockquote><blockquote type="cite">*Prof. Dr. Moazzem Hossain *<br></blockquote><blockquote type="cite">Ex - Director Disease Control<br></blockquote><blockquote type="cite">Ministry of Health & Family Welfare<br>
</blockquote><blockquote type="cite">Government of Bangladesh<br></blockquote><blockquote type="cite">*Mailing address*:<br></blockquote><blockquote type="cite">Founder Chairman and Project Director<br></blockquote><blockquote type="cite">
Institute of Allergy & Clinical Immunology of Bangladesh (IACIB)<br></blockquote><blockquote type="cite">Room 4 - 5 (2nd Floor), Green Super Market, Green Road<br></blockquote><blockquote type="cite">Dhaka -1205, Bangladesh.<br>
</blockquote><blockquote type="cite">Phone:880-2-8115646 (O )<br></blockquote><blockquote type="cite"> 880-1715038551(Mobile)<br></blockquote><blockquote type="cite">Email: <a href="mailto:directordcbd@gmail.com" target="_blank">directordcbd@gmail.com</a><br>
</blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">
<br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">On 8/9/11, jeffrey shaw <<a href="mailto:jayusp@hotmail.com" target="_blank">jayusp@hotmail.com</a>> wrote:<br>
</blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Date: Tue, 9 Aug 2011 11:58:52 +0100<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">From: <a href="mailto:paul.kaye@york.ac.uk" target="_blank">paul.kaye@york.ac.uk</a><br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Subject: Leishmaniasis Pathology Network<br></blockquote></blockquote>
<blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote>
</blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">
<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> Dear all,<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> Invitation to participate in a global pathology<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> network for<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> research and training in leishmaniasis (LeishPathNet)<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> You may recall the Dormy House meeting in 2008<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> and some of<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> the plans we put forward? Over<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> the past<br></blockquote>
</blockquote>
<blockquote type="cite"><blockquote type="cite"> couple years, I have also spoken more to a few of you about one<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> idea that was<br></blockquote>
</blockquote><blockquote type="cite"><blockquote type="cite"> formulated at Dormy, namely of setting up a digital pathology<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> network. I have<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> also had numerous discussions with the major equipment<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> manufacturers to see if<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> any of them would be supportive of helping us to develop such an<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">
initiative. There have<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> been two major<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> develoments recently. First,<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> Carl Zeiss<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> is willing to work with us to set up an integrated global digital<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> pathology<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> network (providing a significant financial and technical<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> contribution) and<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> second, the Wellcome Trust is willing to review a pre-proposal to<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> fund the<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> initiative through their new Biomedical Resources Grant scheme<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite">(<a href="http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/Strategic-awards-and-initiatives/wtdv031727.htm" target="_blank">http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/Strategic-awards-and-initiatives/wtdv031727.htm</a>)<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> .<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> I have attached an outline of the project that<br></blockquote>
</blockquote><blockquote type="cite"><blockquote type="cite"> I had sent to<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> the Trust for their initial views, which I think is reasonably<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> self-explanatory.<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> They appeared very<br></blockquote></blockquote>
<blockquote type="cite"><blockquote type="cite"> enthusiastic! The main<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> question now is whether enough of<br></blockquote></blockquote>
<blockquote type="cite"><blockquote type="cite"> you are still supportive? [ I will also be sending this email to<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> others, but please feel free to circulate ]<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">
I think the<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> project will be<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> challenging, but success could have a real impact on the way we<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> conduct<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> business. It should serve not only as a vehicle to enhance<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> research in<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> leishmaniasis, but the model would be equally applicable across<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> a broad range<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> of diseases and global challenges (with leishmaniasis setting<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> the pace).<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> If we wish to<br></blockquote></blockquote><blockquote type="cite">
<blockquote type="cite"> proceed, the requirements<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> are that we submit a pre-proposal to the Trust by Oct 18th 2011.<br></blockquote>
</blockquote><blockquote type="cite"><blockquote type="cite"> This pre-proposal is short (4 sections of 350 words) and<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> requires<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> letters of support from the community.<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> If you are<br></blockquote>
</blockquote><blockquote type="cite"><blockquote type="cite"> supportive of the idea that<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> we try to take this forward (and there is plenty of scope for<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> later iteration<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> of the detail), I would be grateful if you could please provide<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> me with a<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> letter of support by September<br></blockquote>
</blockquote><blockquote type="cite"><blockquote type="cite"> 12th<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> 2011, indicating whether you would like to be a network<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> partner if the bid<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> is successful. You could<br></blockquote>
</blockquote><blockquote type="cite"><blockquote type="cite"> also be<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> supportive but not wish to become directly involved at this<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> stage, and such<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> letters are equally valuable. Your letter might also stress the<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> added value<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> that the network could provide, its importance for research and<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> training and/or<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> for progressing the translational agenda.<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> It would also be an opportunity to indicate whether your<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> group (or<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> institute, if multiple groups) would be interested in bidding to<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">
be one of the<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> initial ?designated laboratories?.<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> If there is<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> sufficient support to<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> proceed and if subsequently the pre-proposal is successful (we<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> will know on 22nd<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> Nov), then I will need a few volunteers to help finalise the<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> full proposal,<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> which will be due on Jan 26th 2012.<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> A funding decision will be made on May 26th<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> 2012.<br>
</blockquote>
</blockquote><blockquote type="cite"><blockquote type="cite"> Best wishes<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> and of course I am happy to<br></blockquote></blockquote><blockquote type="cite">
<blockquote type="cite"> discuss any points further (though I will be out of the UK from<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> Aug 10 ?Sept<br></blockquote></blockquote>
<blockquote type="cite"><blockquote type="cite"> 12)<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> Paul<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">
<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">
<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">
<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"> --<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Professor Paul Kaye, Ph.D., FRCPath.<br></blockquote></blockquote>
<blockquote type="cite"><blockquote type="cite">Deputy Dean (Research), Hull York Medical School, and<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Director, Centre for Immunology and Infection<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Department of Biology and Hull York Medical School<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">University of York<br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Wentworth Way<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">York YO10 5YW<br></blockquote></blockquote><blockquote type="cite">
<blockquote type="cite">United Kingdom<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Tel: <a href="tel:%2B44%20%280%291904%20328840" value="+441904328840" target="_blank">+44 (0)1904 328840</a><br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Fax: <a href="tel:%2B44%20%280%291904%20328844" value="+441904328844" target="_blank">+44 (0)1904 328844</a><br></blockquote></blockquote><blockquote type="cite">
<blockquote type="cite">Email: <a href="mailto:paul.kaye@york.ac.uk" target="_blank">paul.kaye@york.ac.uk</a> <mailto:<a href="mailto:paul.kaye@york.ac.uk" target="_blank">paul.kaye@york.ac.uk</a>><br></blockquote>
</blockquote>
<blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Centre Administrator and PA: Elizabeth Greensted<br></blockquote></blockquote><blockquote type="cite">
<blockquote type="cite">Tel: 01904 328845<br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Email: <a href="mailto:liz.greensted@york.ac.uk" target="_blank">liz.greensted@york.ac.uk</a> <mailto:<a href="mailto:liz.greensted@york.ac.uk" target="_blank">liz.greensted@york.ac.uk</a>><br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Centre Email: <a href="mailto:cii@york.ac.uk" target="_blank">cii@york.ac.uk</a> <mailto:<a href="mailto:cii@york.ac.uk" target="_blank">cii@york.ac.uk</a>><br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Centre website: <a href="http://www.york.ac.uk/cii" target="_blank">http://www.york.ac.uk/cii</a><br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Times Higher Education University of the Year 2010<br></blockquote></blockquote>
<blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite">Email disclaimer: <a href="http://www.york.ac.uk/docs/disclaimer/email.htm" target="_blank">http://www.york.ac.uk/docs/disclaimer/email.htm</a><br>
</blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite"><blockquote type="cite"><br></blockquote></blockquote><blockquote type="cite">-------------- next part --------------<br>
</blockquote><blockquote type="cite">A non-text attachment was scrubbed...<br></blockquote><blockquote type="cite">Name: Letter Leish UK.doc<br></blockquote><blockquote type="cite">Type: application/msword<br></blockquote>
<blockquote type="cite">Size: 46080 bytes<br></blockquote><blockquote type="cite">Desc: not available<br></blockquote><blockquote type="cite">URL: <<a href="http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110810/73f2ae6a/attachment.doc" target="_blank">http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110810/73f2ae6a/attachment.doc</a>><br>
</blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">------------------------------<br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">_______________________________________________<br>
</blockquote><blockquote type="cite">Leish-l mailing list<br></blockquote><blockquote type="cite"><a href="mailto:Leish-l@lineu.icb.usp.br" target="_blank">Leish-l@lineu.icb.usp.br</a><br></blockquote><blockquote type="cite">
<a href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l" target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a><br></blockquote><blockquote type="cite"><br></blockquote><blockquote type="cite">
<br></blockquote><blockquote type="cite">End of Leish-l Digest, Vol 44, Issue 3<br></blockquote><blockquote type="cite">************************************** <br></blockquote><br><br><br><br><br>=======<br>Email scanned by PC Tools - No viruses or spyware found.<br>
(Email Guard: 7.0.0.26, Virus/Spyware Database: 6.18330)<br><a href="http://www.pctools.com/" target="_blank">http://www.pctools.com/</a><br>=======<br>_______________________________________________<br>Leish-l mailing list<br>
<a href="mailto:Leish-l@lineu.icb.usp.br" target="_blank">Leish-l@lineu.icb.usp.br</a><br><a href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l" target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a><br>
</div></blockquote></div><br><div> <div style="word-wrap:break-word;font-size:14px"><div><p style="margin-top:0px;margin-right:0px;margin-bottom:0px;margin-left:0px"><span style="font-size:medium"><font size="3"><span style="font-size:12px"><br>
</span></font></span></p></div></div></div></div></div></div><br>_______________________________________________<br>
Leish-l mailing list<br>
<a href="mailto:Leish-l@lineu.icb.usp.br">Leish-l@lineu.icb.usp.br</a><br>
<a href="http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l" target="_blank">http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l</a><br>
<br></blockquote></div><br><br clear="all"><div><br></div>-- <br><div style="text-align:center"><span style="font-family:verdana, sans-serif"><b>Carlos H. N. Costa, MD, DSc.</b></span></div><div style="text-align:center">
<span style="font-family:verdana, sans-serif"><b>Sociedade Brasileira de Medicina Tropical </b></span></div><div style="text-align:center"><b><span style="font-family:verdana, sans-serif"></span></b><span style="font-family:verdana, sans-serif"><b>(Brazilian Society of Tropical Medicine)</b></span></div>
<div style="text-align:center"><span style="font-family:verdana, sans-serif"><b>President</b></span></div><div style="text-align:center"><span style="font-family:verdana, sans-serif"><b><br></b></span></div><div style="text-align:center">
<span style="font-family:verdana, sans-serif"><b>Universidade Federal do Piauí</b></span></div><div><div style="text-align:center"><span style="font-family:verdana, sans-serif"><b>Instituto de Doenças Tropicais Natan Portella</b></span></div>
<div style="text-align:center"><font face="verdana, sans-serif"><b>Rua Artur de Vasconcelos 151-Sul</b></font></div><div><div style="text-align:center"><span style="font-family:verdana, sans-serif"><b>64001-450 Teresina-PI</b></span></div>
<font face="verdana, sans-serif"><div style="text-align:center"><b>Brazil</b></div><b><div style="text-align:center"><span style="font-weight:normal"><b>Telephones: +55 86 3221-3413 (work); +55 86 8838-3303 (mobile).</b></span></div>
</b><div style="text-align:center"><br></div><span style="font-size:x-small"><div style="text-align:center">Aviso: As informações contidas nesta mensagem são CONFIDENCIAIS, protegidas pelo sigilo legal, por direitos autorais e destinadas exclusivamente à pessoa ou organização para a qual a mensagem foi destinada.</div>
<div style="text-align:center">Warning: This message is meant only for the intended recipient of the transmission. It is forbidden any unauthorized use, alteration, reproduction and distribution. If you are not the correct recipient, please notify us immediately by return e-mail and delete this message from your system.</div>
</span></font></div></div><br>
</div>